Skip to main content
OpenTrials
Completed

NCT Number: NCT02163213

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D

To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

About this study

This is an open label study evaluating the impact of SBI 5.0 g twice daily on

  • nutritional status (plasma amino acid profile and kynurenine to tryptophan ratio),
  • intestinal permeability (in vivo) and
  • mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines status in patients with IBS-D.

Plasma, duodenal and stool samples will be collected. Fifteen eligible subjects will be enrolled to receive SBI for 8 weeks (SBI 5.0g BID for 8 weeks).

Intestinal permeability will be measured in vivo by two sugar urine excretion(s) after oral ingestion.

Biopsies from the distal second or third portion of the duodenum will be obtained endoscopically, to measure mRNA expression of tight junction proteins and markers of immune function,

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65y
  • Male or non-pregnant female
  • IBS by Rome III criteria with predominant symptom of diarrhea
  • Baseline 14 day diary showing average of 2 days per week with >3 bowel movements per day

Exclusion criteria

  • Intake of medications that interfere with the study
  • Antibiotic within prior 2 weeks and throughout study
  • Prior abdominal surgery except appendectomy
  • Active gastrointestinal diagnosis other than IBS
  • History of allergy or intolerance to beef or to any ingredient in the investigational product
  • Uncontrolled psychiatric disorders (includes significant depression or suicidal ideation), in investigator's judgment
  • Use of tobacco products within the past six months or nonsteroidal antiinflammatory drugs or aspirin within the past week (since they all may affect intestinal permeability)
  • Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies.
  • For two days prior to studies, patients are instructed to avoid ingestion of artificial sweeteners such as Splenda trademark (TM) (sucralose), Nutrasweet TM (aspartame), foods containing lactulose or mannitol.

Treatment and study plan

Serum-derived bovine immunoglobulin protein isolate (SBI)

Other

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D

Primary outcomes

  1. Change in epithelial barrier function, and mucosal expression of barrier-associated genes

    Time frame: 10 weeks

    The primary endpoints for the study are change from baseline in mucosal expression of tight junction proteins (ZO-1, occludin, claudin)

Secondary outcomes

  1. Change in body measurements, amino acid metabolism, abdominal pain, and baseline stool frequency and consistency.

    Time frame: 10 weeks

    The secondary endpoints for the study is change from baseline in amino acid metabolism

Other outcomes

  1. Duodenal and fecal microbiomes

    Time frame: 10 weeks

    Exploratory endpoints: Duodenal biopsy microbiome

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jun 13, 2014
Registry last updated
Oct 18, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.